Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL2094256 Target Snapshot

Angiotensin II receptor · PROTEIN FAMILY · Homo sapiens

934Compounds
67Assays
5Approved Drugs
566.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Protein identity stays anchored to UniProt P30556. Use UniProt P30556 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt P30556 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Angiotensin II receptor as ChEMBL target CHEMBL2094256, mapped to UniProt P30556. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Angiotensin II receptor
PROTEIN FAMILY · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL2094256
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P30556
Type-1 angiotensin II receptor
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Angiotensin II receptor is the right protein anchor across sources, using UniProt P30556 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelType-1 angiotensin II receptor
UniProt AccessionP30556
Component TypeProtein
Sequence Length359 aa

Type-1 angiotensin II receptor

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Angiotensin II receptor, mapped to UniProt P30556. ChEMBL maps the protein component as Type-1 angiotensin II receptor. Sequence length is 359 aa.

Mapped IDP30556
Review nameAngiotensin II receptor
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

5
Approved
3
Phase II
Assay Mix

Activity Type Distribution

IC50227.0
KI2.0
KD337.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL47177 10.9 Kd 0.01259 Preclinical
CHEMBL416477 10.7 Kd 0.01995 Preclinical
CHEMBL125218 10.33 Kd 0.04677 Preclinical
CHEMBL293511 10.3 Kd 0.05012 Preclinical
CHEMBL418226 10.3 Kd 0.05012 Preclinical
CHEMBL92542 10.25 Kd 0.05623 Preclinical
CHEMBL938 10.18 IC50 0.066 Approved
CHEMBL295854 10.1 IC50 0.08 Preclinical
CHEMBL907 10.09 Kd 0.08128 Preclinical
CHEMBL41194 10.04 Kd 0.0912 Clinical
Distribution

pChEMBL Value Distribution

18
5.0
20
5.5
34
6.0
29
6.5
67
7.0
88
7.5
94
8.0
70
8.5
39
9.0
29
9.5
pChEMBL
Approved Drugs

Approved Drugs

IRBESARTAN
CHEMBL1513
Approved 1997
LOSARTAN
CHEMBL191
Approved 1995
LOSARTAN POTASSIUM
CHEMBL995
Approved 1995
SARALASIN
CHEMBL938
Approved 1982
Assay Landscape

Assay Landscape

67
Total Assays
251
Tested Compounds
2
Assay Types
Functional — 37 assays, 251 compounds
BAO Format Assays Compounds Avg pChEMBL
tissue-based format 28 231 7.8
assay format 4 11 8.6
organism-based format 4 0
cell-based format 1 9 7.6
Binding — 30 assays, 244 compounds
BAO Format Assays Compounds Avg pChEMBL
protein format 20 57 8.1
tissue-based format 5 120 8.2
assay format 3 44 7.6
cell membrane format 2 23 5.4

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine